Foer et al. followed this with the publication of research that compared the rates of asthma exacerbations and symptoms in people with type 2 diabetes using a GLP-1 receptor agonist with those using other antidiabetic drugs (SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, or basal insulin) to intensify the treatment of diabetes. This evidence concerns the gene SLC5A2 and asthma.